JHVEPhoto/iStock Editorial via Getty Images Eli Lilly ( NYSE: LLY ) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk ( NVO ) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials, as sales from its new GLP-1.
